您的位置: 首页 > 农业专利 > 详情页

Anti-C5 antibodies having improved pharmacokinetics
专利权人:
Alexion Pharmaceuticals; Inc.
发明人:
Bruce A. Andrien, Jr.,Douglas L. Sheridan,Paul P. Tamburini,Yi Wang
申请号:
US15160364
公开号:
US09663574B2
申请日:
2016.05.20
申请国别(地区):
US
年份:
2017
代理人:
摘要:
The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充